Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas

Waldemar Debinski, Denise M. Gibo, Stanley W. Hulet, James Connor, G. Yancey Gillespie

Research output: Contribution to journalArticle

183 Scopus citations

Abstract

Glioblastoma multiforme (GBM) is an incurable brain tumor. Due to the striking heterogeneity that characterizes GBM, there is no known tumor- specific antigen or receptor that is expressed by a majority of GBM patients. We found that virtually all studied human GBM specimens (23 samples) abundantly expressed a receptor for interleukin (IL)-13 in situ, whereas normal human brain had few, if any, IL-13-binding sites. The GBM-associated IL-13 receptor was both quantitatively and qualitatively different from and, thus, more restrictive than the shared signaling receptor of normal tissue: it was IL-4 independent. The receptor for IL-13 was overexpressed by a majority of cancer cells in situ. Furthermore, cytotoxins targeted to this more restrictive IL-13R produced cures in animals bearing xenografts of human high-grade gliomas. Thus, unexpectedly, the receptor for an immune regulatory cytokine may be a long sought marker and, concomitantly, a unique imaging site and therapeutic target for GBM, the most malignant and the most heterogeneous of brain tumors.

Original languageEnglish (US)
Pages (from-to)985-990
Number of pages6
JournalClinical Cancer Research
Volume5
Issue number5
StatePublished - May 1999

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas'. Together they form a unique fingerprint.

  • Cite this

    Debinski, W., Gibo, D. M., Hulet, S. W., Connor, J., & Gillespie, G. Y. (1999). Receptor for interleukin 13 is a marker and therapeutic target for human high-grade gliomas. Clinical Cancer Research, 5(5), 985-990.